In Re: Zofran (Ondansetron)Products Liability Litigation

Track this case

Case overview

Case Number:

1:15-md-02657

Court:

Massachusetts

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

F. Dennis Saylor, IV

Firms

Companies

Glenmark Pharmaceuticals Ltd.

Sectors & Industries:

Healthcare
- Generic

February 05, 2019
GSK Can't Escape MDL Alleging Zofran Caused Birth Defects

A Massachusetts federal judge on Tuesday denied GlaxoSmithKline a quick win in multidistrict litigation claiming its anti-nausea drug Zofran led to birth defects, saying GSK has not proven the U.S. Food and Drug Administration would have rejected a stricter warning label.
September 13, 2018
FDA Never Saw Birth-Defect Tests On GSK Drug, Families Say

Families suing GlaxoSmithKline who claim the anti-nausea medication Zofran led to birth defects argued Thursday in Massachusetts federal court that crucial tests were not shown to the U.S. Food and Drug Administration when it rejected a correlation between the drug and defects as the families tried to beat the company's motion for summary judgment.
July 20, 2018
GlaxoSmithKline Says FDA Rejected Zofran Birth Defects

GlaxoSmithKline argued Thursday that it cannot be held liable for birth defects caused after pregnant women were prescribed its postoperative nausea drug Zofran because the U.S. Food and Drug Administration has since rejected any scientific correlation between the medication and defects.
June 27, 2018
GSK Planned Off-Label Pitch At Every OB-GYN, Families Say

"Bombshell" depositions have allegedly revealed GlaxoSmithKline employed — but later fired — a small team of specialists to secure hedge fund money and deploy pharmaceutical sales representatives to ask every OB-GYN in the country to prescribe an anti-nausea drug off-label, attorneys for hundreds of families suing the company told a Massachusetts federal judge Wednesday.
May 22, 2018
GSK Gets Generic Suits Tossed From Zofran MDL

Three women who took a generic version of a nausea treatment developed by GlaxoSmithKline LLC can't sue the branded drugmaker for injuries allegedly caused by a generic product, a Massachusetts federal judge said Monday when dismissing their allegations from multidistrict litigation.
May 17, 2018
GSK, Zofran Users To Pick 16 Potential MDL Bellwether Cases

GlaxoSmithKline and the families who claim its anti-nausea medication Zofran caused various birth defects will each select eight cases to probe and possibly bring to trial in the multidistrict litigation's final discovery phase, a Massachusetts federal judge ruled Thursday.
April 25, 2018
GSK, Zofran Users Bicker Over Scope Of Patient Discovery

Counsel for GlaxoSmithKline and families who claim its anti-nausea medication Zofran caused various birth defects argued in Boston federal court Wednesday over how many patients should be targeted for individual discovery in the multidistrict product liability litigation.
March 27, 2018
GSK Has One Week To Hand Over Zofran Data, Judge Says

A Massachusetts federal judge late Monday gave GlaxoSmithKline one week to provide families who blame its popular anti-nausea drug Zofran for causing birth defects a list of all available information involving adverse effects caused by the drug.
March 14, 2018
GSK Says It Can't Find Marketing Contracts In Zofran MDL

GlaxoSmithKline attorneys have looked for eight months but cannot find contracts with at least 40 partners involved in marketing its hit antiemetic drug that allegedly caused birth defects in hundreds of children, counsel to the pharmaceutical giant and families suing it said Wednesday.
February 26, 2018
GSK Hid Zofran Data From FDA, Families Say

Families who blame GlaxoSmithKline and its popular anti-nausea drug Zofran for causing birth defects asked a Massachusetts federal judge on Friday to force the company to hand over data on all adverse effects caused by the drug, including information the families say GSK did not reveal to federal regulators.